Cannara Biotech's CEO is Zohar Krivorot, appointed in Jan 2019, has a tenure of 7.5 years. total yearly compensation is CA$525.00K, comprised of 61.9% salary and 38.1% bonuses, including company stock and options. directly owns 0.94% of the company’s shares, worth €1.08M. The average tenure of the management team and the board of directors is 3.1 years and 6.2 years respectively.
Key information
Zohar Krivorot
Chief executive officer
CA$525.0k
Total compensation
CEO salary percentage
61.90%
CEO tenure
7.5yrs
CEO ownership
0.9%
Management average tenure
3.1yrs
Board average tenure
6.2yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Zohar Krivorot's remuneration changed compared to Cannara Biotech's earnings?
Date
Total Compensation
Salary
Company Earnings
May 31 2026
n/a
n/a
CA$11m
Feb 28 2026
n/a
n/a
CA$10m
Nov 30 2025
n/a
n/a
CA$12m
Aug 31 2025
CA$525k
CA$325k
CA$13m
May 31 2025
n/a
n/a
CA$16m
Feb 28 2025
n/a
n/a
CA$13m
Nov 30 2024
n/a
n/a
CA$7m
Aug 31 2024
CA$300k
CA$300k
CA$6m
May 31 2024
n/a
n/a
CA$5m
Feb 29 2024
n/a
n/a
CA$6m
Nov 30 2023
n/a
n/a
CA$9m
Aug 31 2023
CA$300k
CA$300k
CA$7m
May 31 2023
n/a
n/a
CA$5m
Feb 28 2023
n/a
n/a
CA$3m
Nov 30 2022
n/a
n/a
CA$3m
Aug 31 2022
CA$75k
CA$75k
CA$2m
May 31 2022
n/a
n/a
CA$884k
Feb 28 2022
n/a
n/a
CA$1m
Nov 30 2021
n/a
n/a
CA$1m
Aug 31 2021
n/a
n/a
-CA$2m
May 31 2021
n/a
n/a
-CA$7m
Feb 28 2021
n/a
n/a
-CA$11m
Nov 30 2020
n/a
n/a
-CA$13m
Aug 31 2020
CA$92k
CA$92k
-CA$12m
May 31 2020
n/a
n/a
-CA$12m
Feb 29 2020
n/a
n/a
-CA$12m
Nov 30 2019
n/a
n/a
-CA$13m
Aug 31 2019
CA$150k
CA$150k
-CA$12m
Compensation vs Market: Zohar's total compensation ($USD374.53K) is about average for companies of similar size in the German market ($USD469.62K).
Compensation vs Earnings: Zohar's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Zohar Krivorot (49 yo)
7.5yrs
Tenure
CA$525,000
Compensation
Mr. Zohar Krivorot serves as Chief Executive Officer of Cannara Biotech Inc. since 2019, Director since December 31, 2018 and is its Founder, Chairman of the Board. He served as President at Cannara Biotec...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Zohar Krivorot
Founder
7.5yrs
CA$525.00k
0.94% € 1.1m
Nicholas Sosiak
COO & Interim CFO
5.7yrs
CA$525.00k
0.83% € 955.4k
Avi Krivorot
Chief Technology Officer
no data
CA$425.00k
no data
Scott Carroll
Vice President of Investor Relations & Commercial Strategy
less than a year
no data
0.0031% € 3.6k
Brian Sherman
General Counsel & VP Legal Affairs
no data
no data
0.17% € 194.2k
Nick Van Dam
Vice President of Sales
2.5yrs
no data
no data
Sabrina Salvo
Vice President of Marketing
less than a year
no data
no data
France Landry
Vice President of Human Resources
3.7yrs
no data
no data
Etienne Ledoux
Executive Officer
no data
CA$300.00k
no data
3.1yrs
Average Tenure
Experienced Management: 8CB0's management team is considered experienced (3.1 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Zohar Krivorot
Founder
7.6yrs
CA$525.00k
0.94% € 1.1m
Donald Olds
Independent Lead Director
5.7yrs
CA$70.00k
0.24% € 280.6k
Derek Stern
Non-Independent Director
7.6yrs
CA$30.00k
0.41% € 466.3k
Mary Durocher
Independent Director
6.2yrs
CA$40.00k
1.52% € 1.7m
Justin Cohen
Independent Director
1.3yrs
CA$35.00k
no data
6.2yrs
Average Tenure
59yo
Average Age
Experienced Board: 8CB0's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/31 09:46
End of Day Share Price
2026/07/31 00:00
Earnings
2026/05/31
Annual Earnings
2025/08/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cannara Biotech Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.